Protagenic Therapeutics, Inc. received a notification letter from the Nasdaq Listing Qualifications Staff regarding non-compliance with Nasdaq rules.
The company's stockholders' equity fell below the minimum requirement, and there was a delay in filing periodic reports.
Protagenic Therapeutics is taking steps to address the deficiencies and expects to file the required Form 10-Q soon.
Non-Compliance Notification
Received notice from Nasdaq about deficiencies in stockholders' equity and filing periodic reports.
Delisting Determination
Nasdaq issued a determination to delist Protagenic Therapeutics' securities due to non-compliance.
Hearing Request
Company will request a hearing before a Nasdaq Hearings Panel to address the deficiencies.
- Protagenic Therapeutics is facing the risk of delisting from the Nasdaq due to non-compliance with listing requirements.
- Stock trading remains active during the appeal process, but there are uncertainties about the outcome.
Protagenic Therapeutics is actively working on rectifying the compliance issues to maintain its listing on the Nasdaq. The outcome of the hearing will be crucial for the company's future trading status.